LifeCell Reports Preliminary 4Q:05 Financials
BY JOHN CHOPACK, JANUARY 26, 2006
LifeCell reported that it anticipates 4Q:05 product revenues of $27 million which is a 69% increase over the 4Q:04.
Product revenues were driven by an 84% increase in Alloderm sales. Orthopedic Product Revenues, which consist of GraftJacket and AlloCraft DBM sales, increased 24% to $2.0 million in the 4Q:05.
Preliminary product revenues for the full year 2005 are $93.3 million which is a 60% increase over 2004. The Company anticipates that 2005 EPS per diluted share will be in the previously guided range of $0.35 to $0.36 which is in-line with analysts expectations.
The Company expects 2006 revenues to range between $124 to $130 million which represents growth of 33-39%. Product mix is expected to be 86% reconstructive, 8% orthopedic and 6% urogynecology. Earning-per-share for 2006 is expected to range between $0.59 and $0.63.
Currently, LifeCell's stock is trading at 59x trailing twelve month earnings and 37x 2006 earnings which represents one of the most expensive stocks in the orthopedic sector. However, LifeCell's stock also increased 144% in the last 12 months which is one of the best returns in the orthopedic space.
